On October 11, 2023, the U.S. Food and Drug Administration (FDA) approved a combination of Braftovi (encorafenib) and Mektovi (binimetinib) for people with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. BRAF is a less common [...]
Every year, lung cancer professionals from across the globe gather to connect and learn at the World Conference for Lung Cancer (WCLC). Members of the GO2 team just returned from WCLC 2023 hosted in Singapore, where they presented GO2’s [...]
Small cell lung cancer (SCLC), which represents about 15% of all lung cancer diagnoses, is an often-aggressive form of lung cancer that has historically been difficult to treat. However, the science driving new treatments for SCLC is moving faster than [...]
GO2 for Lung Cancer to Receive a $250,000 Engagement Award to Build Capacity for Patient Engagement in Research Within a Stigmatized Lung Cancer Community San Carlos, CA and Washington, DC – Today GO2 for Lung Cancer (GO2) announced its Chief [...]
The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring where oncologists and other physicians, researchers, industry members, and advocacy organizations like GO2 come together to share and learn the latest and most exciting news on [...]
SAN CARLOS, Calif. and WASHINGTON, D.C. (July 28, 2023) – GO2 for Lung Cancer (GO2) announced today that it presented David Carbone, MD, PhD with the 2023 Bonnie J. Addario Lectureship Award for his work developing treatments for lung cancer. GO2 honored Dr. Carbone [...]
By Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer New research on metastatic (stage 4) non-small cell lung cancer (NSCLC) was a hot topic at the 2023 American Society of Clinical Oncology (ASCO) meeting. Data from [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer While the past decade has seen the development of many new therapies for lung cancer, these drugs are typically first approved for metastatic cancer (cancer that has [...]
By Heather Law, MA, Associate Director, GO2’s Lung Cancer Registry Lung cancer screening is unavailable for many people at risk for lung cancer. At the 2023 American Society of Clinical Oncology (ASCO) meeting, early results from groundbreaking studies offered [...]
The Women and Lung Cancer Research and Preventive Service Act Will Expand Resources to Understand the Science of Lung Cancer in Women San Carlos, CA and Washington, DC – Today, GO2 for Lung Cancer (GO2) applauded the efforts of [...]